Clinical Trial Detail

NCT ID NCT03601507
Title Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer
Recruitment Suspended
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors University of Arizona
Indications

pharynx squamous cell carcinoma

Therapies

Alpelisib

Age Groups: adult child senior

Additional content available in CKB BOOST